Acadia gets FDA's fast track tag for Alzheimer's disease candidate
- Posted on July 21, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Acadia gets FDA's fast track tag for Alzheimer's disease candidate
Acadia Pharmaceuticals ACAD announced that the FDA has granted Fast Track designation to its investigational, highly selective, 5-HT2A receptor inverse agonist, remlifanserin, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fulfill unmet medical needs to get...
